Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Long

Karyopharm Therapeutics Inc.NASDAQ

Description

⋅ Jun 22, 2020 4:56 PM

KPTI: Karyopharm Therapeutics Inc.
2020-06-22 11:25:10
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Beyond Technical Analysis

Comments

st0nkz

⋅ Jun 22, 2020 4:58 PM

99% owed by intuitions as well.